Compare URG & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URG | PRTC |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 477.8M | 386.7M |
| IPO Year | N/A | N/A |
| Metric | URG | PRTC |
|---|---|---|
| Price | $1.25 | $16.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $2.52 | N/A |
| AVG Volume (30 Days) | ★ 9.9M | 5.0K |
| Earning Date | 11-03-2025 | 08-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $39,411,000.00 | $6,391,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $183.54 | N/A |
| P/E Ratio | ★ N/A | $7.83 |
| Revenue Growth | 138.94 | ★ 1265.60 |
| 52 Week Low | $0.55 | $13.30 |
| 52 Week High | $2.35 | $23.35 |
| Indicator | URG | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 51.09 |
| Support Level | $1.17 | $16.44 |
| Resistance Level | $1.46 | $17.17 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 27.62 | 55.29 |
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.